These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 15955702

  • 1. Recent advances in tumor-targeting anticancer drug conjugates.
    Jaracz S, Chen J, Kuznetsova LV, Ojima I.
    Bioorg Med Chem; 2005 Sep 01; 13(17):5043-54. PubMed ID: 15955702
    [Abstract] [Full Text] [Related]

  • 2. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I.
    Acc Chem Res; 2008 Jan 01; 41(1):108-19. PubMed ID: 17663526
    [Abstract] [Full Text] [Related]

  • 3. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV.
    Acc Chem Res; 2008 Jan 01; 41(1):98-107. PubMed ID: 17705444
    [Abstract] [Full Text] [Related]

  • 4. Antibody-cytotoxic agent conjugates for cancer therapy.
    Chen J, Jaracz S, Zhao X, Chen S, Ojima I.
    Expert Opin Drug Deliv; 2005 Sep 01; 2(5):873-90. PubMed ID: 16296784
    [Abstract] [Full Text] [Related]

  • 5. The powerful applications of polyunsaturated fatty acids in improving the therapeutic efficacy of anticancer drugs.
    Wang J, Luo T, Li S, Zhao J.
    Expert Opin Drug Deliv; 2012 Jan 01; 9(1):1-7. PubMed ID: 22171694
    [Abstract] [Full Text] [Related]

  • 6. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
    Brumlik MJ, Daniel BJ, Waehler R, Curiel DT, Giles FJ, Curiel TJ.
    Expert Opin Drug Deliv; 2008 Jan 01; 5(1):87-103. PubMed ID: 18095930
    [Abstract] [Full Text] [Related]

  • 7. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR, Hinman LM, Beyer CF, Greenberger LM, Lin C, Lindh D, Menendez AT, Wallace R, Durr FE, Upeslacis J.
    Bioconjug Chem; 2005 Jan 01; 16(2):346-53. PubMed ID: 15769088
    [Abstract] [Full Text] [Related]

  • 8. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.
    Rege K, Patel SJ, Megeed Z, Yarmush ML.
    Cancer Res; 2007 Jul 01; 67(13):6368-75. PubMed ID: 17616696
    [Abstract] [Full Text] [Related]

  • 9. [Targeting of antitumor drugs with monoclonal antibodies].
    Monneret C, Florent JC.
    Bull Cancer; 2000 Nov 01; 87(11):829-38. PubMed ID: 11125291
    [Abstract] [Full Text] [Related]

  • 10. The evolution of antibodies into versatile tumor-targeting agents.
    Lin MZ, Teitell MA, Schiller GJ.
    Clin Cancer Res; 2005 Jan 01; 11(1):129-38. PubMed ID: 15671537
    [Abstract] [Full Text] [Related]

  • 11. Cell killing by antibody-drug conjugates.
    Kovtun YV, Goldmacher VS.
    Cancer Lett; 2007 Oct 08; 255(2):232-40. PubMed ID: 17553616
    [Abstract] [Full Text] [Related]

  • 12. Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents.
    Casi G, Neri D.
    J Med Chem; 2015 Nov 25; 58(22):8751-61. PubMed ID: 26079148
    [Abstract] [Full Text] [Related]

  • 13. Antibody-drug conjugates as targeted cancer therapeutics.
    Sun Y, Yu F, Sun BW.
    Yao Xue Xue Bao; 2009 Sep 25; 44(9):943-52. PubMed ID: 20055167
    [Abstract] [Full Text] [Related]

  • 14. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA, Chari RV.
    Clin Cancer Res; 2011 Oct 15; 17(20):6389-97. PubMed ID: 22003066
    [Abstract] [Full Text] [Related]

  • 15. Antibody-drug conjugates in tumor therapy.
    Sammet B, Steinkühler C, Sewald N.
    Pharm Pat Anal; 2012 Mar 15; 1(1):65-73. PubMed ID: 24236714
    [Abstract] [Full Text] [Related]

  • 16. The design of cytotoxic-agent-antibody conjugates.
    Ghose T, Blair AH.
    Crit Rev Ther Drug Carrier Syst; 1987 Mar 15; 3(4):263-359. PubMed ID: 2435417
    [Abstract] [Full Text] [Related]

  • 17. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y, Noy R, Wels WS, Benhar I.
    Cancer Lett; 2007 Nov 08; 257(1):124-35. PubMed ID: 17698286
    [Abstract] [Full Text] [Related]

  • 18. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
    Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY.
    Bioconjug Chem; 2007 Nov 08; 18(1):41-9. PubMed ID: 17226956
    [Abstract] [Full Text] [Related]

  • 19. Ligand-based targeted therapy for cancer tissue.
    Das M, Mohanty C, Sahoo SK.
    Expert Opin Drug Deliv; 2009 Mar 08; 6(3):285-304. PubMed ID: 19327045
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.
    Burke PJ, Senter PD, Meyer DW, Miyamoto JB, Anderson M, Toki BE, Manikumar G, Wani MC, Kroll DJ, Jeffrey SC.
    Bioconjug Chem; 2009 Jun 08; 20(6):1242-50. PubMed ID: 19469529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.